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Matrix-degrading metalloproteinases play a major 
role in tissue remodeling. Recent studies have shown 
that enzymes of this class are constitutively expressed 
primarily by stromal cells and not by epithelium. Here 
we present immunohistochemical evidence that ma-
trilysin is localized within epidermal cells in develop-
ing skin and in tumor cells of cutaneous malignancies. 
The expression of matrilysin protein in developing 
fetal skin (6 - 15 weeks) is localized primarily to the 
germinative basal cell layer of fetal epidermis and 
early appendageal buds. The buds continue to express 
matrilysin during mesenchymal invasion. As develop-
ment progresses (15 - 19 weeks) matrilysin is concen-
trated only in cells at the distal portion of the invading 
follicular and sweat gland appendageal cords. In adult 
skin, matrilysin was localized specifically to the outer 
root sheath of the hair follicles and the secretory cells 
of the eccrine glands but was absent in the epidermis. 
M at·rix metalloproteinases (MMPs) play a major role in tissue remodeling associated with cell-stromal interactions in both physiologic and pathologic processes [1- 3]. The skin is an attrac-tive system for studying epithelial-stromal inter-
actions during fetal morphogenesis and tumor invasion. However, 
little is known about how the expression of MMPs correlates with 
dermal invasion associated with developing epidermal appendages 
and whether this relates to localized tumor invasion associated with 
certain skin tumors (basal cell carcinomas [BCCs] and squamous cell 
carcinomas [SCCs]) . 
In previous studies [4] we have shown that in aggressive cutane-
ous tumors a significant quantity of 92-kDa type IV collagenase 
(gelatinase B) was deposited extracellularly both within the extra-
cellular matrix adjacent to the tumor nests and in their basement 
membrane zone. This enzyme, and also several other MMPs (stro-
melysin and 72-kDa type IV collagenase / gelatinase A), did not play 
a major role in skin morphogenesis during fetal development [4]. 
Matrilysin (PUMP) has been found in tumor cells at the epithelial-
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Nodulocystic, keratotic, adenoid basal cell carcino-
mas (Bees) did not express matrilysin. In contrast, in 
the more aggressive morpheaform (infiltrative) Bees 
and recurrent Bees, matrilysin was localized at the 
tumor-stromal interface. In squamous cell carcinomas 
matrilysin was present in tumor cells at the stromal 
interface surrounding the tumor nests. 
The demonstration of matrilysin protein in ger-
minal basal cells during fetal skin development and its 
presence in tumor cells at the stromal junction suggests 
that this enzyme may contribute to the proteolytic ac-
tivity associated with cell-extracellular matrix inter-
actions during appendageal development and tumor 
invasion. Key words: matrix metalloproteinase/ morphogen-
esis/ cell invasion/ skin tumors. ] Invest Dermatol 103:482-
487, 1994 
stromal junction [5 - 7] whereas the related MMPs, interstitial colla-
genase [1,2] and stromelysin-3 [8,9], have been localized to stromal 
fibroblasts also at the stromal-epithelial interface, suggesting that 
these enzymes are involved in tumor progression [10,11]. 
Matrilysin (PUMP) is a unique member of the extracellular ma-
trix (ECM) metalloproteinase gene family [12] and differs from 
other MMPs by the absence of the carboxyl terminal, hemopexin-
like domain [13,14] . Matrilysin has a broad spectrum of substrate 
specificity ill lIitro; it can degrade fibronectin, larninin, elastin, pro-
teoglycans, gelatin, and entactin [15,16]. The ability of matrilysin 
to degrade entactin [16], which is anchored to both laminin and type 
IV collagen, and possibly to also degrade type IV collagen [17], 
suggests that matrilysin might be involved in proteolytic degrada-
tion of the basement membrane. 
The present study examines the immunocytochemical localiza-
tion of matrilysin in fetal skin during epidermal morphogenesis and 
compares this to its presence in cutaneous tumors. Matrilysin ex-
pression by epidermal cells at the basement membrane zone junc-
tion of invading appendageal and tumor cells suggests that this 
enzyme may playa major role in ECM degradation during cutane-
ous development and tumor invasion. 
MATERIALS AND METHODS 
Forty specimens, including 28 BCCs (12 were nodulocystic, three keratotic, 
four adenoid, four morpheaform [infi ltrative], and five recurrent), nine 
SCCs, one baso-squamous cell carcinoma (BSCC), and two benign sweat 
gland tumors (SGTs) were obtained by surgical excision. Five normal skin 
samples were obtained from healthy volunteers, 25 - 40 years of age, after 
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informed consent. Fetal skin samples originated from spontaneous abortions 
at gestational ages from 6 to 27 weeks. Specimens were embedded in Tissue-
Tek O.C.T. 4583 compound and stored at -70°C. Serial cryostat sections 
(5 - 7}.l in thickness) were prepared as previously described [4], and incubated 
with an affinity-purified polyclonal antibody against matrilysin [17] (a gift 
from Dr. H. G. Welgus, Washington University). The specificity of this 
antibody was confirmed by Western analysis [17]. Three-step indirect im-
munofl uorescence was used for anti-matrilysin antibody, for which a biotin-
ylated anti-rabbit complex was used as the second antibody, followed by 
incubation with avidin-biotin-fluorescein isothiocyanate-containing anti-
body. Incubation with non-immune rabbit immunoglobulin (Ig)G or ornis-
sion of the primary antibody were used as controls. Hematoxylin-stained 
slides of all tumors were examined by light microscopy and graded. 
RESULTS 
Matrilysin is Developmentally Regulated in Fetal and Adult 
Skin At the earliest stage of gestation examined (6 weeks) a bright 
intracellular staining pattern for matrilysin was present both in peri-
dermal and in basal stratum germinativum cells of the epidermis 
(Fig la), but was not seen in the dermal mesenchymal cells. At 8 
weeks of gestation, when fetal epidermis was beginning to stratify 
from a rwo- to a three-layered epithelium, all cell layers including 
the basal germinative cells showed an intense staining for matrilysin 
(Fig lb). By 10 weeks of gestation the enzyme was localized intra-
cellularly next to the basement membrane zone, forming an appar-
ent linear fluorescent band (Fig lc). In contrast, the suprabasal 
epidermal cell compartment (stratum intermedium) continued to 
show matrilysin surrounding the inner portion of the cell mem-
brane (Fig lc). 
At the time of appendageal bud formation (in hair follicles from 
the sca lp at 12 and 15 weeks, in those from the trunk at 18 and 20 
weeks, in eccrine glands from the sole skin at 14 and 16 weeks, and 
in those from trunk skin at 23 and 25 weeks), bright enzyme immu-
nostaining was first observed in all cell layers of the appendageal 
buds (Fig ltl). As appendageal buds developed and began to invade 
the ECM, matrilysin was concentrated in the germinal cells at the 
distal portion of the invading follicular and sweat gland appenda-
geal buds immediately next to the basement membrane zone (Fig 
le,f). In addition, the suprabasal epidermal keratinocytes of the 
stratum intermedium overlying the developing appendages (both 
hair follicle and sweat gland) showed a decrease in the intensity of 
staining for matrilysin. 
During appendageal bud invasion, a marked change in the stain-
ing pattern for matrilysin was found in the germinal epidermal basal 
cells berween the appendageal buds. The staining intensity of intra-
cellular matrilysin in the germinal basal cells of the inter-appenda-
geal epidermis was significantly decreased and now showed a punc-
tate staining pattern for matrilysin (Fig 19). 
As hair follicle development progressed, the epithelial cells of the 
outer root sheath stained positively for matrilysin. Although matri-
lysin was also present in the developing eccrine glands, there was no 
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difference in the distribution of enzyme protein between the pri-
mary germ cells of follicular or sweat gland appendageal buds. 
By 20 weeks, matrilysin protein was no longer found in either the 
basal or suprabasal cell layers of the epidermis of fetal sole and scalp 
skin (Fig lh) but the enzyme was still present in basal keratinocytes 
of trunk epidermis (Fig li). At 25 and 27 weeks of gestation devel-
oping epidermis now showed the morphologic features of the post-
natal state (stratification, absence of bud formation, and keratiniza-
tion). Immunostaining for matrilysin was now completely absent in 
epidermal keratinocytes but was present in the outer root sheath of 
the hair follicles (Fig lj) and in the secretory portion of the eccrine 
glands (Fig lj). Matrilysin protein was not found in either epider-
mal cells or stromal cells of adult skin. Occasional matrilysin-posi-
tive epithelial cells were seen in the outer root sheath of hair folli-
cles. In contrast, the secretory cells of all the eccrine glands stained 
intensely for matrilysin. 
Our findings show that the presence of matrilysin protein cor-
relates with the morphogenetic-dependent epidermal changes, 
suggesting that production of matrilysin is developmentally regu-
lated. 
Distribution of Matrilysin in Fetal Skin is Recapitulated in 
Skin Tumors To determine whether matrilysin also plays a role 
in the behavior of skin tumors, we compared the immunostaining 
pattern seen in developing fetal epidermis with the distribution of 
matrilysin immunoreactivity in epithelial-derived skin tumors. In-
terestingly, immunostaining for matrilysin was absent in the nodu-
locystic, keratotic, and adenoid BCCs examined. In contrast, matri-
lysin was present in those cancers examined considered to display 
more aggressive behavior [1 8-20), e.g., morpheaform (infiltrative) 
and recurrent BCCs, and SCCs. In these tumors several immuno-
staining patterns were identified. The most frequently observed 
pattern of matrilysin staining was seen in both morpheaform and 
recurrent BCCs. In most of these tumors the enzyme was present 
only in tumor cells at the tumor-stromal interface as a single cell 
layer forming an apparent linear band of enzyme surrounding the 
tumor nests (Fig 2a). In some morpheaform and recurrent BCCs 
(Fig 2b,c), a more complex immunostaining pattern for matrilysin 
was found. In recurrent (and morpheaform) BCCs matrilysin-posi-
tive cells were found within the tumor nests at the tumor-stromal 
interface, and in occasional tumor cells extending a short distance 
from the parent tumor nests (Fig. 2b,c). 
Of interest, the distribution of matrilysin in the epidermis adja-
cent ~o the t~mor nests differed from non-tumor-associated epi-
dermIS. Matnlys1l1 lIllmunoreactivity was present in basal cells of 
the adjacent normal-appearing epidermis and occasionally was also 
present in the suprabasal keratinocytes. 
A somewhat different pattern of matrilysin immunostaining was 
found in SCCs. Matrilysin-positive tumor cells were organized into 
small groups of cells (Fig 2J) or seen as single bright-staining tumor 
Figure 1. Immunohistochemical localization of matrilysin in human fetal epidermis. a)Fetal skin at 6 weeks of gestation. Intense staining for 
matri lysin is seen in both peridermal (~) and basal germinative cells (-+). Immunoreactivity is not present in the mesenchymal cells of the ECM. Bar, 200l1m. 
b) Fetal skin from trunk at 8 weeks of gestation. There is bright intracellular staining of the periderm (~), the stratum intermedium (0), and the germinative 
basal cells (-+) of the epidermis. Bar, 100 }.lm. c)At 10 weeks of gestation, matrilysin is localized at the distal portion of the germinative basal cells forming an 
apparent linear immuno-f1uorescent band next to the basement membrane zone (-+). The periderm continues to stain brightly (~). Bar, 50 jlm. d)Appendageal 
bud (0) from fetal scalp at 15 weeks of gestation. Matrilysin is present in all epidermal cell layers of the developing appendageal buds and also shows a linear 
appearing immunostaining pattern along the basement membrane zone (-+). Bar, 50 }.lm. e) Early appendageal bud invasion seen in sweat glands from the sole at 
16 weeks of development. Matrilysin is concentrated predominantly in the distal portion of the cells (-+) of the invading sweat gland buds (0) and is still present 
in the overlying periderm (~) . Bar, 100 }.lm.J) Hair follicle at 20 weeks of development. Matrilysin is present in gemlinative cells of the fo llicular cord next to 
the basement membrane zone (-+) but clearly absent from the dermal papilla (dp) and the surrounding extracellu lar matrix. Hair fo llicle fornls as a bulb around 
the specialized mesenchymal cells of the dermal papilla. Bar, 100 }.lm. Insert represents a fo llicle developing from an appendageal bud showing a higher power 
view of matrilysin containing germinative cells at the basement membrane zone (-+). Bar, 50 }.lm. g) Inter-appendageal epidermis at the same stage shown in e. 
The staining intensity of matrilysin in the germinal basal cells of the inter-appendageal epidermis is significantly decreased and shows a punctate staining 
pattern (-+). Cells of the periderm continue to stain brightly (0). Bar, 50 }.lm. h)At 20 weeks of gestation, matrilysin protein is present only in cells of the 
periderm ~) of fetal sole epidermis. In contrast, in trunk skin at 20 weeks of gestation, i) the enzyme is sti ll present in the basal germinative cell layer of the 
epidermis (-+). Sweat gland appendageal cord shows a decreased intensity of staining for l1latrilysin in suprabasal epidermal keratinocytes ~) . The dist.~1 
portion of the developing sweat gland (0) continues to stain brightly for matrilysin. Bar, 200 }.lm. JjTransverse section of hair fo llicle and sweat gland from 
23-week-old fetal trunk skin. At this stage of development hair follicles and sweat glands are fu lly developed. The outer root sheath of the hair follicle (-+) and 
secretory portion of the eccrine glands (0) stain brightly for matrilysin. Bar, 100 }.lm. 
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Figure 2. Distribution of matrilysin in Bees and sees. a) Recurrent BeC. Intense immunostaining for matrilysin is seen in a single layer of tumor cells 
next to the tumor-stromal interface (--) and surrounding each tumor nest (t). Bar, 200 J.lm. b) Recurrent BCC. Matrilysin-positive cells (--) are present within 
the tumor nests and at the tumor-stromal interface of each developing tumor nest. Matrilysin protein is absent in the epidermal cells (*) above the tumor nests. 
Bar, 100 }Jm. c) Recurrent BCC. Matrilysin-positive cells arc found within the tumor nests (t), at the tumor-stromal interface (--), and in occasional cells (~) 
extending from the parent tumor nest. Bar, 100 }Jm. d) Well-differentiated SCC. Matrilysin-positive tumor cells arc organized into small groups of cells (-+) or 
e) distributed as single enzyme-containing cells (~) among the predominantly enzyme-negative cells of the tumor nests (t) . Bar, 50 J.lm.f) Well differentiated 
sec. Matrilysin-positive tumor cells are present at the tumor-stromal interface in the tumor nests (t), (--). Bar, 100 J.lm. g) Poorly differentiated SCC. 
Matrilysin is present in tumor cells (--) around all the tumor nests (t). ECM surrounding the tumor (*) is devoid of enzyme-containing stromal cells. Bar, 
100f1,m. 
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cells (Fig 2e) distributed among the predominantly enzyme-nega-
tive tumor cells. In well differentiated SCCs enzyme-containing 
tumor cells were found infrequently at the tumor-stromal interface 
surrounding the tumor nests (Fig 2f). In contrast, in poorly differ-
entiated SCCs matrilysin was localized to tumor cells at the ECM 
junction around nearly all tumor nest~ (Fig 2g). Matrilysin was 
absent in the inflammatory cells present m the ECM surroundmg all 
tumor types examined. 
Interestingly, in the two benign sweat gland tumors studied, ma-
trilysin immunoreactivity was not detected in the tumor cells or in 
the stroma. 
DISCUSSION 
The observations presented in this study show that in developing 
skin, and in aggressive cutaneous tumors, matrilysin is localized in 
epidermal and tumor cells. This indicates that the expression of 
matrilysin differs markedly from that of other MMPs that are con-
stitutively produced primarily by stromal cells [4,8,9,21]. From the 
earliest stages of gestation (6 weeks), matrilysin in fetal skin was 
found in both peridermal and germinal basal cells (stratum germi-
nativum) of developing epidermis. Between 8 and 10 weeks of 
gestation, as the epidermis begins to stratify, changes in the intracel-
lular distribution pattern of matrilysin were observed. The supraba-
sal cel l layers of fetal epidermis (stratum intermedium) continued to 
stain positive for matrilysin protein. However, in the basal cells of 
the stratum germinativum, the enzyme was now concentrated pre-
dominantly at the epidermal-stromal interface, forming a linear-ap-
pearing immunofluorescent band. 
Appendageal bud formation begins at 12-15 weeks (scalp, sole), 
and at 19-24 weeks (trunk). At this time matrilysin was localized 
predominantly in germinal and suprabasal epidermal cells of bud-
ding hair follicles and sweat glands. As appendageal development 
progressed, matrilysin was restricted to a specific population of epi-
dermal cells involved in the downward invasion of the appendageal 
buds into the ECM, forming epidermal cell cords. During the for-
mation of hair follicles and sweat glands, as the epidermal cords 
invaded the stroma, the suprabasal epidermal keratinocytes of both 
the developing appendages and the inter-appendageal epidermis no 
longer stained for matrilysin. By 25 - 27 weeks of gestation, fetal 
epidermis was completely devoid of matrilysin immunoreactivity. 
This was also true for postnatal and adult epidermis. 
Matrilysin expression by epidermal cells at the epidermal-dermal 
junction during early cutaneous development and at later gesta-
tional stages, where the enzyme is restricted to the invading appen-
dageal cords, suggests that matrilysin may contribute to proteolytic 
activity required for rapid, localized, ECM turnover. The functional 
role of matrilysin in postnatal hair follicle root sheath and sweat 
glands remains to be determined. 
We examined several different skin tumors for the presence of 
matrilysin to determine whether there was a relationship between 
matrilysin and tumor invasion, similar to the dermal invasion that 
occurs during epidermal appendageal development. Significantly, 
in skin tumors such as recurrent and morpheaform BCCs, and in 
secs, matrilysin protein was prominently expressed in tumor cells 
in close contact with the basement membrane zone. In contrast, in 
less aggressive tumors, e.g., in nodular, nodulocystic, and adenoid 
BCCs, immunostaining for matrilysin was absent. 
Although the expression of matrilysin protein varied among 
tumors considered more aggressive (morpheaform and recurrent 
Bees, and SeCs) [18-20] several immunostaining patterns were 
identified. In the most frequently observed pattern, matrilysin was 
localized in tumor cells at the stromal interface surrounding the 
tumor nests, showing an interesting parallel with the enzyme pat-
tern seen in the basal germinative cells of fetal epidermis and the 
appendageal buds. As with fetal epidermis, it was not possible to 
determine, at the level of the light microscope, whether any enzyme 
was present extracellularly adjacent to the cell membrane. Our 
findings show that in developing epidermal appendages and in 
tumor cells, matrilysin immunoreactivity was always present in 
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close association with the basement membrane zone; matrilysin was 
never seen within mesenchymal cells, endothelial cells, or monocy-
tic and lymphatic cells of the dermis. 
Another pattern of matrilysin immunoreactivity was present in 
SCCs and was characterized by bright staining of single tumor cells, 
or of a group of several tumor cells, which were distributed freely 
among other tumor cells devoid of matrilysin. The presence of 
matrilysin immunoreactivity in a few selected tumor cells localized 
within the tumor nests suggests that transient expression of matrily-
sin occurs, which may reflect its normal transitory function in re-
sponse to changes in cell differentiation [22]. 
Matrilysin has also been localized to tumor cells of gastric, colon 
[5,6], and prostatic [7] carcinomas, and in agreement with our ob-
servations, was not detected in stromal cells. A correlation was 
present between the expression of matrilysin in gastric and colon 
carcinomas and lymph node metastasis. Of interest are the studies of 
Powell et at [10], who transfected matrilysin cDNA into a tumori-
genic but nonmetastatic human prostate tumor cell line that does 
not constitutively express matrilysin. The transfected tumor cells 
expressing matrilysin acquired a highly invasive phenotype il'l vivo 
with an associated increased loss of basement membrane, suggesting 
that matrilysin functions in the initial invasion of tumor cells . The 
accumulation of matrilysin protein, as we have shown previously 
for 92-kDa type IV collagenase [4], correlates directly with the 
aggressive behavior of the skin tumors studied. However, unlike 
matrilysin, 92-kDa type IV collagenase [1], interstitial collagenase 
[23], stomelysin-l [21], and stromelysin-3 are expressed primarily 
by stromal cells in close proximity to the tumor but not by tumor 
cells. 
Our data show that matrilysin is not only a specific component of 
a population of germinative fetal epidermal cells but is also consist-
ently expressed in aggressive epidermal derived skin tumors in a 
distribution pattern similar to that seen in developing epidermis and 
its appendages. Matrilysin has a broad substrate specificity that 
overlaps with certain other matrix metalloproteinases [13,15,16]. 
The demonstration of matrilysin protein in germinal basal cells 
during fetal skin development and the presence of matrilysin in 
tumor cells at the stromal junction suggests that this enzyme may 
contribute to the changes occurring in fetal epidermis during ap-
pendageal development, and in tumor invasion. 
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